Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries

The purpose of this study is to gather information about the long-term effects and safety of treatment with Rapamune in transplant patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Transplantation

Sex eligibility

All sexes

Study type

Observational

Primary location

Gothenburg, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Transplantation patients treated with sirolimus (Rapamune).

Exclusion criteria

Patients must be able to give informed consent.

Treatment and study plan

sirolimus

Drug

Transplantation patients treated with sirolimus who consent to participate in the study (register)

Other names: Rapamune

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

A Rapamune Follow-up Registry in Transplant Recipients in the Nordic Countries, "Wrap-up"

Important dates

Study start: 2005
Primary completion: 2008
Study completion: 2008
First posted: Sep 19, 2005
Registry last updated: Jan 31, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed